Phase 2 Glaucoma Trial, Recruiting NCT05426044 Sponsor: Christopher Kai Shun Leung Condition: Glaucoma
Back to Glaucoma

Phase 2 Glaucoma Trial, Recruiting

NCT05426044
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People whose best vision with glasses or contact lenses is at least 20/40
  • People whose eye pressure measured at 24 mmHg or below at both the screening and baseline appointments
  • People who have shown progressive thinning of certain layers at the back of the eye (RNFL and/or GCIPL), detected by specialised eye scans, over the past 3 years in at least one eye

Who may not be able to join:

  • People who have diabetes, kidney disease, or liver disease
  • People with an abnormally high level of short-sightedness, known as pathological myopia
  • People with cognitive conditions such as Alzheimer's disease or similar impairments
  • People who have conditions other than glaucoma that may cause vision loss or changes to the appearance of the optic nerve
  • People who are unable to complete reliable visual field tests (a type of eye assessment)
  • People whose eye scan (OCT) images are not of sufficient quality for analysis

Please note: Both eyes may be included in the study if both meet the eligibility criteria, as determined by the trial site.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Christopher LEUNG, MD, The University of Hong Kong

Phone: (852)3962-1405

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Christopher Kai Shun Leung
Registry
ClinicalTrials.gov
Start date
1 June 2025
Est. completion
31 December 2027

Where this trial is recruiting

Hong Kong

Primary endpoints

Rates of RNFL/GCIPL thinning (Evaluation of Neuroprotection); Change in visual field sensitivity (Evaluation of Neuroenhancement)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov